At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 171 enrolled
Drug / intervention
GLS-5310 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Randomized, Combined Phase I Dose-escalation and Phase IIa Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Immunogenicity of GLS-5310 DNA Vaccine, Administered Intradermally Against SARS-CoV-2 in Healthy Adults
In Brief
A Phase 2 clinical trial evaluating GLS-5310 and Placebo for SARS-CoV-2. Completed, enrolled 171 participants across 1 site.
Detailed Summary
This clinical trial will evaluate the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2(COVID-19) in healthy volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2
CountriesSouth Korea
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartDec 2020
Primary CompletionMar 2021
Study CompletionMay 2023
TodayJul 2026
First PostedDec 17, 2020
Enrollment StartDec 31, 2020
Primary CompletionMar 3, 2021
Study CompletionMay 10, 2023
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.5 years ago
Interventions
GLS-5310biological
GLS-5310 DNA plasmid vaccine
Placebobiological
Placebo